Biofrontera Inc.
BFRI
$0.9252
-$0.0385-4.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.19% | 8.54% | 18.53% | 1.30% | 34.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.19% | 8.54% | 18.53% | 1.30% | 34.05% |
| Cost of Revenue | -39.15% | -20.60% | -1.79% | 6.25% | 50.35% |
| Gross Profit | 82.67% | 40.15% | 39.38% | -3.97% | 18.14% |
| SG&A Expenses | 33.35% | -6.34% | -9.32% | -3.07% | -30.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.29% | -1.82% | -1.31% | 4.93% | -9.97% |
| Operating Income | -0.16% | 16.83% | 55.71% | -12.22% | 40.28% |
| Income Before Tax | -2,137.55% | 59.72% | -139.74% | 10.65% | 97.59% |
| Income Tax Expenses | 5.00% | -200.00% | 50.00% | 200.00% | 42.86% |
| Earnings from Continuing Operations | -1,971.60% | 59.73% | -139.59% | 10.61% | 97.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,971.60% | 59.73% | -139.59% | 10.61% | 97.39% |
| EBIT | -0.16% | 16.83% | 55.71% | -12.22% | 40.28% |
| EBITDA | -2.27% | 15.38% | 55.13% | -12.51% | 40.94% |
| EPS Basic | -1,027.33% | 83.56% | -111.20% | 78.84% | 99.30% |
| Normalized Basic EPS | -1,194.16% | 83.04% | 73.92% | 65.87% | 99.27% |
| EPS Diluted | -1,027.33% | 83.56% | -122.43% | 78.84% | 99.30% |
| Normalized Diluted EPS | -1,194.16% | 83.04% | 73.92% | 65.87% | 99.27% |
| Average Basic Shares Outstanding | 83.67% | 144.89% | 253.49% | 322.45% | 274.18% |
| Average Diluted Shares Outstanding | 83.67% | 144.89% | 253.49% | 322.45% | 274.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |